Serum insulin-like growth factor-binding protein-2 (IGFBP-2) is increased and IGFBP-3 is decreased in patients with prostate cancer: correlation with serum prostate-specific antigen.

Kanety, Hannah; Madjar, Y; Dagan, Yaron; Levi, Jelena; Papa, Moshe Z.; Pariente, Clara; Goldwasser, Benad; Karasik, Avraham

doi:10.1210/jcem.77.1.7686915

Cited by 101 publications

(88 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Normal and malignant prostate cells produce IGF-1 and several of its binding proteins that can act in a paracrine or autocrine manner (Cohen et al, 1991;Pietrzjowski et al, 1993;Kimura et al, 1996). IGF-binding proteins are found abundantly in prostate secretions, and their serum levels have been reported to differ between patients with and without prostate cancer (Cohen et al, 1993;Kanety et al, 1993). Moreover, prostate cells express IGF-1 receptors and are very sensitive to stimulation by IGFs (Cohen et al, 1991;Kimura et al, 1996).…”

Section: Discussionmentioning

confidence: 99%

Insulin-like growth factor 1 in relation to prostate cancer and benign prostatic hyperplasia

Mantzoros

Τζώνου²,

Signorello³

et al. 1997

Br J Cancer

330

170

View full text Add to dashboard Cite

Summary Blood samples were collected from 52 incident cases of histologically confirmed prostate cancer, an equal number of cases of benign prostatic hyperplasia (BPH) and an equal number of apparently healthy control subjects. The three groups were matched for age and town of residence in the greater Athens area. Steroid hormones, sex hormone-binding globulin, and insulin-like growth factor 1 (IGF-1) were measured in duplicate by radioimmunoassay in a specialized US centre. Statistical analyses were performed using multiple logistical regression. The results for IGF-1 in relation to prostate cancer and BPH were adjusted for demographic and anthropometric factors, as well as for the other measured hormones. There was no relation between IGF-1 and BPH, but increased values of this hormone were associated with increased risk of prostate cancer; an increment of 60 ng ml-' corresponded to an odds ratio of 1.91 with a 95% confidence interval of 1.00-3.73. There was also some evidence for an interaction between high levels of testosterone and IGF-1 in relation to prostate cancer. This finding suggests that, in addition to testosterone, IGF-1 may increase the risk of prostate cancer in humans.Insulin-like growth factor 1 (IGF-1) is secreted mainly by the liver but is also produced in several other tissues in response to growth hormone (LeRoith et al, 1992). It has been documented that IGF-1 can act in an autocrine and paracrine manner to promote normal growth and malignant cellular proliferation (Daughaday, 1990;LeRoith et al, 1992). The importance of IGF-1 as a major growthregulating molecule has been established for cells in culture (Goustin et al, 1986;LeRoith et al, 1992; Webster et al, 1996) and has also been suggested by studies in vivo (Ezzat and Melmed, 1991). IGF-1 and several of its binding proteins are produced by normal prostate cells (Cohen et al, 1991) as well as prostate cancer cells (Pietrzjowski et al, 1993;Kimura et al, 1996) and act locally through activation of IGF-1 receptors to stimulate cell proliferation (Angelloz-Nicoud and Binoux, 1995). In addition to its established autocrine and paracrine action, IGF-1 has important endocrine functions (LeRoith et al, 1992). However, the role, if any, of circulating IGF-1 in the aetiology of benign prostatic hyperplasia (BPH) and prostate cancer has not received sufficient attention.We have previously reported results concerning the role of serum steroid hormones in the aetiology of BPH and prostate cancer ) from a matched case-control study undertaken in Athens, Greece. Circulating IGF-1 was measured in the same sera, and we present the relevant results in this report. SUBJECTS AND METHODSIn the context of a large, ongoing case-control study of diet in relation to prostate cancer and BPH, blood samples were collected during an 18-months period from 52 incident cases of histologically confirmed prostate cancer and 52 cases of BPH with matching for age (±1 year) and town of residence within the greater Athens area. Within the constraints imposed by this ...

show abstract

Section: Discussionmentioning

confidence: 99%

Insulin-like growth factor 1 in relation to prostate cancer and benign prostatic hyperplasia

Mantzoros

Τζώνου²,

Signorello³

et al. 1997

Br J Cancer

330

170

View full text Add to dashboard Cite

show abstract

“…IGFBPs have also been considered in relation to prostate cancer, particularly IGFBP-3 in epidemiological studies Glycemic index in chronic disease LS Augustin et al (Chan et al, 1998;Wolk et al, 1998). Most investigators have reported an inverse association between IGFBP-3 and prostate cancer risk (Chan et al, 1998;Thrasher et al, 1996;Kanety et al, 1993), although others have found no association (Wolk et al, 1998). A possible role of IGFs in prostate carcinogenesis is also suggested by mechanistic studies on Suramin, a drug used in the treatment of advanced prostate cancer, which was shown to suppress IGF-levels (Miglietta et al, 1993;Sartor et al, 1994).…”

Section: Prostate Cancermentioning

confidence: 99%

Glycemic index in chronic disease: a review

et al. 2002

View full text Add to dashboard Cite

Aim: The intent of this review is to critically analyze the scientific evidence on the role of the glycemic index in chronic Western disease and to discuss the utility of the glycemic index in the prevention and management of these disease states. Background: The glycemic index ranks foods based on their postprandial blood glucose response. Hyperinsulinemia and insulin resistance, as well as their determinants (eg high energy intake, obesity, lack of physical activity) have been implicated in the etiology of diabetes, coronary heart disease and cancer. Recently, among dietary factors, carbohydrates have attracted much attention as a significant culprit, however, different types of carbohydrate produce varying glycemic and insulinemic responses. Low glycemic index foods, characterized by slowly absorbed carbohydrates, have been shown in some studies to produce beneficial effects on glucose control, hyperinsulinemia, insulin resistance, blood lipids and satiety. Method: Studies on the short and long-term metabolic effects of diets with different glycemic indices will be presented and discussed. The review will focus primarily on clinical and epidemiological data, and will briefly discuss in vitro and animal studies related to possible mechanisms by which the glycemic index may influence chronic disease.

show abstract

“…There are several consistent reports that link risk of prostate cancer with high serum levels of IGF-I (Mantzoros et al, 1997;Chan et al, 1998;Wolk et al, 1998;Stattin et al, 2000;Chokkalingam et al, 2001). Decreased levels of IGFBP-3, the most abundant IGFBP in the circulation, have been found in prostate cancer patients and in those with metastatic diseases (Kanety et al, 1993;Chan et al, 1998;Chokkalingam et al, 2001).…”

mentioning

confidence: 99%

Polymorphism of the insulin gene is associated with increased prostate cancer risk

Melman

Liu

et al. 2003

Br J Cancer

View full text Add to dashboard Cite

High insulin levels are linked with increased cancer risk, including prostate cancer. We examined the associations between prostate cancer with polymorphisms of the insulin gene (INS) and its neighbouring genes, tyrosine-hydroxylase and IGF-II (TH and IGF2). In this study, 126 case -control pairs matched on age, race, and countries of origin were genotyped for +1127 INS-PstI in INS, -4217 TH-PstI in TH, and +3580 IGF2-MspI in IGF2. The homozygous CC genotype of +1127 INS-PstI occurred in over 60% of the population. It was associated with an increased risk of prostate cancer in nondiabetic Blacks and Caucasians (OR ¼ 3.14, P ¼ 0.008). The CC genotype was also associated with a low Gleason score o7 (OR ¼ 2.60, P ¼ 0.022) and a late age of diagnosis (OR ¼ 2.10, P ¼ 0.046). Markers in the neighbouring genes of INS showed only null to modest associations with prostate cancer. The polymorphism of INS may play a role in the aetiology of prostate cancer. Given the high prevalence of the CC genotype and its association with late age of onset of low-grade tumours, this polymorphism may contribute to the unique characteristics of prostate cancer, namely a high prevalence of indolent cancers and the dramatic increase in incidence with age.

show abstract

Serum insulin-like growth factor-binding protein-2 (IGFBP-2) is increased and IGFBP-3 is decreased in patients with prostate cancer: correlation with serum prostate-specific antigen.

Cited by 101 publications

References 17 publications

Insulin-like growth factor 1 in relation to prostate cancer and benign prostatic hyperplasia

Insulin-like growth factor 1 in relation to prostate cancer and benign prostatic hyperplasia

Glycemic index in chronic disease: a review

Polymorphism of the insulin gene is associated with increased prostate cancer risk

Contact Info

Product

Resources

About